INCB28060, with the CAS number 1029714-89-3, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its potential therapeutic applications. It is classified as a selective inhibitor of certain kinases, which are enzymes that play crucial roles in various cellular processes, including cell growth and division. The compound is characterized by its ability to modulate signaling pathways, making it a candidate for the treatment of various diseases, including certain types of cancer. INCB28060 exhibits a specific binding affinity to its target, which contributes to its efficacy and selectivity. Additionally, its chemical structure includes functional groups that enhance its solubility and bioavailability, important factors for drug development. As with many investigational compounds, ongoing studies are focused on understanding its pharmacokinetics, safety profile, and overall therapeutic potential. The compound's development reflects the broader trend in medicinal chemistry towards targeted therapies that minimize side effects while maximizing therapeutic benefits.

INCB28060

1029714-89-3: INCB28060, with the CAS number 1029714-89-3, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its potential therapeutic applications. It is classified as a selective inhibitor of certain kinases, which are enzymes that play crucial roles in various cellular processes, including cell growth and division. The compound is characterized by its ability to modulate signaling pathways, making it a candidate for the treatment of various diseases, including certain types of cancer. INCB28060 exhibits a specific binding affinity to its target, which contributes to its efficacy and selectivity. Additionally, its chemical structure includes functional groups that enhance its solubility and bioavailability, important factors for drug development. As with many investigational compounds, ongoing studies are focused on understanding its pharmacokinetics, safety profile, and overall therapeutic potential. The compound's development reflects the broader trend in medicinal chemistry towards targeted therapies that minimize side effects while maximizing therapeutic benefits.

Capmatinib xHCl

<p>Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50</p>

CAS 1029714-89-3

INCB28060

Capmatinib xHCl

Ref: 54-BUP09131

Capmatinib xHCl

Ref: TM-T8416

Capmatinib Hydrochloride

Ref: ST-EA-CP-C134002